AYTU BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.904 USD | +2.26% |
|
+4.10% | +2.26% |
| Feb. 14 | Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024 | |
| Feb. 14 | Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M | MT |
Valuation
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 31.49 | 170.8 | 126.1 | 26.62 | 8.838 | 16.17 | - | - |
| Enterprise Value (EV) 1 | 31.49 | 170.8 | 126.1 | 26.62 | 8.838 | 16.17 | 16.17 | 16.17 |
| P/E ratio | -0.54 x | -4.73 x | -1.44 x | -0.18 x | -0.31 x | -1.3 x | 5.81 x | 18.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 4.3 x | 6.18 x | 1.92 x | 0.28 x | 0.08 x | 0.19 x | 0.21 x | 0.23 x |
| EV / Revenue | 4.3 x | 6.18 x | 1.92 x | 0.28 x | 0.08 x | 0.19 x | 0.21 x | 0.23 x |
| EV / EBITDA | - | - | -2.7 x | -1.03 x | -1.79 x | 1.4 x | 0.93 x | 1.09 x |
| EV / FCF | - | -6,018,603 x | - | - | -1,723,182 x | - | - | - |
| FCF Yield | - | -0% | - | - | -0% | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 83.3 | 601 | 1,259 | 1,929 | 5,524 | 5,568 | - | - |
| Reference price 2 | 378.0 | 284.0 | 100.2 | 13.80 | 1.600 | 2.904 | 2.904 | 2.904 |
| Announcement Date | 9/26/19 | 10/6/20 | 9/27/21 | 9/27/22 | 9/27/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.32 | 27.63 | 65.63 | 96.67 | 107.4 | 83.55 | 77.08 | 71.01 |
| EBITDA 1 | - | - | -46.75 | -25.85 | -4.942 | 11.52 | 17.38 | 14.9 |
| EBIT 1 | -16.85 | -20.94 | -58.87 | -111.6 | -12.33 | -0.465 | 4.376 | 1.018 |
| Operating Margin | -230.13% | -75.76% | -89.7% | -115.41% | -11.48% | -0.56% | 5.68% | 1.43% |
| Earnings before Tax (EBT) 1 | -27.13 | -13.62 | -58.03 | -110.3 | -17.05 | -11.4 | 3.214 | 1.018 |
| Net income 1 | -27.13 | -13.62 | -58.29 | -110.2 | -17.05 | -12.23 | 2.732 | 0.865 |
| Net margin | -370.64% | -49.29% | -88.81% | -113.97% | -15.88% | -14.64% | 3.54% | 1.22% |
| EPS 2 | -696.0 | -60.00 | -69.60 | -75.00 | -5.110 | -2.230 | 0.5000 | 0.1600 |
| Free Cash Flow | - | -28.37 | - | - | -5.129 | - | - | - |
| FCF margin | - | -102.68% | - | - | -4.78% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 9/26/19 | 10/6/20 | 9/27/21 | 9/27/22 | 9/27/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 21.9 | 23.12 | 24.2 | 27.45 | 27.66 | 26.28 | 22.73 | 30.73 | 22.1 | 22.93 | 17.35 | 21.17 |
| EBITDA 1 | -5.569 | - | -6.81 | -4.858 | - | -2.016 | -6.364 | 4.645 | 0.437 | 5.083 | 0.495 | 3.725 |
| EBIT 1 | -27.7 | -11.29 | -54.66 | -17.91 | -1.653 | -4.193 | -8.558 | 2.809 | -1.504 | 2.364 | -2.26 | 0.935 |
| Operating Margin | -126.5% | -48.84% | -225.86% | -65.26% | -5.98% | -15.96% | -37.65% | 9.14% | -6.81% | 10.31% | -13.03% | 4.42% |
| Earnings before Tax (EBT) 1 | -27.96 | -11.55 | -53.07 | -17.7 | -2.881 | -6.693 | -7.2 | -2.457 | -8.12 | 0.608 | -3.541 | -0.346 |
| Net income 1 | -27.85 | -11.55 | -53.07 | -17.7 | -2.881 | -6.693 | -7.2 | -2.457 | -8.12 | -0.22 | -3.541 | -0.346 |
| Net margin | -127.19% | -49.94% | -219.32% | -64.49% | -10.42% | -25.47% | -31.67% | -7.99% | -36.74% | -0.96% | -20.41% | -1.63% |
| EPS 2 | -21.80 | -8.800 | -35.80 | -7.000 | -1.200 | -2.150 | -1.930 | -0.5900 | -1.480 | -0.0400 | -0.6400 | -0.0600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 2/14/22 | 5/16/22 | 9/27/22 | 11/14/22 | 2/21/23 | 5/11/23 | 9/27/23 | 11/14/23 | 2/14/24 | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -28.4 | - | - | -5.13 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0.06 | - | 2.34 | - | - | - | - | - |
| Capex / Sales | 0.82% | - | 3.57% | - | - | - | - | - |
| Announcement Date | 9/26/19 | 10/6/20 | 9/27/21 | 9/27/22 | 9/27/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.904
USD
Average target price
8
USD
Spread / Average Target
+175.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.26% | 16.17M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- AYTU Stock
- Financials Aytu BioPharma, Inc.
